CGON CG Oncology, Inc.

Nasdaq cgoncology.com


$ 38.87 $ -1.38 (-3.43 %)    

Tuesday, 11-Nov-2025 15:59:59 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 38.84
$ 39.96
$ 34.12 x 15
$ 41.75 x 100
$ 35.80 - $ 40.48
$ 14.80 - $ 45.56
1,440,460
na
nm
$ 2.14
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Guggenheim analyst Brad Canino initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target ...

Core News & Articles

JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

Jones Trading analyst Soumit Roy initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Targe...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.

 cg-oncology-stock-signals-bullish-momentum-ahead

CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here&#...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-mus...

Core News & Articles

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the la...

Core News & Articles

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48)...

Core News & Articles

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a po...

Core News & Articles

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $...

Core News & Articles

-SEC Filing

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and lowers the price target from $...

Core News & Articles

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION